Bibliography
- Joint United Nations Programme on HIV/AIDS: Global facts and figures. World Health Organization. Report on the global AIDS epidemic 2008, August 2008. Available from: http://data.unaids.org/ pub/GlobalReport/2008/20080715_fs_global_en.pdf. [Last accessed 10 June 2009]
- Centers for Disease Control and Prevention (CDC). HIV prevalence estimates: United States, 2006. MMWR Morb Mortal Wkly Rep 2008;57:1073-6
- Hall HI, Song R, Rhodes P, Estimation of HIV incidence in the United States. JAMA 2008;300:520-9
- Palella FJ Jr, Delaney KM, Moorman AC, Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60
- Lima VD, Hogg RS, Harrigan PR, Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007;21:685-92
- Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293-9
- Hammer SM, Eron JJJr, Reiss P, Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555-70
- Stone VE, Jordan J, Tolson J, Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004;36:808-16
- Moyle G, Gatell J, Perno CF, Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection. AIDS Patient Care STDS 2008;22:459-71
- Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its role in HIV infection and treatment. JAMA 2006;296:815-26
- Lusso P. HIV and the chemokine system: 10 years later. EMBO J 2006;25:447-56
- Westby M, Smith-Burchnell C, Mori J, Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007;81:2359-71
- Barber CG. CCR5 antagonists for the treatment of HIV. Curr Opin Investig Drugs 2004;5:851-61
- Strizki JM, Tremblay C, Xu S, Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005;49:4911-9
- Schurmann D, Fatkenheuer G, Reynes J, Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007;21:1293-9
- Schuermann D. Vicriviroc (formerly SCH 417690): antiviral Activity of a Potent New CCR5 Receptor Antagonist. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janiero, Brazil; July 24-27, 2005 (Poster TuOa0205)
- Ghosal A, Ramanathan R, Yuan Y, Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist. Drug Metab Dispos 2007;35:2186-95
- Sansone A, Keung A, Caceres M, Effect of food on bioavailability of SCH 417690 (vicriviroc) in healthy volunteers. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA; December 17, 2005 (Poster A-1200)
- Seiberling M, Kraan M, Keung A, Similar increase in vicriviroc exposure with co-administration of varying doses of ritonavir in healthy volunteers. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janiero, Brazil; July 24-27, 2005 (Abstract TUPE3.1B06)
- Sansone A, Keung A, Tetteh E, Vicriviroc pharmacokinetics are not significantly altered in the presence of ritonavir-boosted protease inhibitors. XVI International AIDS Conference. Toronto, Canada; August 13-18, 2006 (Poster TUPE0074)
- Kasserra C, Sansone-Parsons A, Keung A, Vicriviroc pharmacokinetic parameters are unchanged when co-administered with darunavir in a ritonavir containing regimen. Ninth annual International Workshop on Clinical Pharmacology of HIV Therapy. New Orleans, LA, USA; April 7-9, 2008 (Abstract P35)
- Saltzman M, Rosenberg M, Kraan M, Pharmacokinetics of SCH 417690 administered alone or in combination with ritonavir or lopinavir/ritonavir. The 6th International Workshop on Clinical Pharmacology of HIV Therapy. Québec City, Québec, Canada; April 28-30, 2005 (Poster 6.6)
- Guillaume M, Kraan M, Keung A, The pharmacokinetics of SCH 417690 when administered alone and in combination with lamivudine/zidovudine. The 6th International Workshop on Clinical Pharmacology of HIV Therapy. Québec City, Québec, Canada; April 28-30, 2005 (Poster 6.10)
- Guillaume M, Kraan M, Soni P, Pharmacokinetics of SCH 417690 administered alone or in combination with tenofovir. The 6th International Workshop on Clinical Pharmacology of HIV Therapy. Québec City, Québec, Canada; April 28-30, 2005 (Poster 6.11)
- Brown KC, Paul S, Kashuba AD. Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet 2009;48:211-41
- Kasserra C, O'Mara E, Lisbon E. Assessment of pharmacokinetic and safety interactions between vicriviroc and CYP3A4 substrates, inhibitors, and inducers. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA; September 12-15, 2009. Poster H-230
- Kasserra C, Adamczyk R, Li J, The effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics. XVII International AIDS Conference. Mexico City, Mexico; August 3-8, 2008 (Abstract TUPE0043)
- ClinicalTrials.gov. 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00523211?term=vicriviroc&phase=2&rank=2. [Last accessed 4 September 2009]
- Gulick RM, Su Z, Flexner C, Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007;196:304-12
- Landovitz RJ, Angel JB, Hoffmann C, Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis 2008;198:1113-22
- Zingman B, Suleiman J, DeJesus E, Vicriviroc in combination therapy with an optimized ART regimen for treatment-experienced subjects: VICTOR-E1. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA; February 3-6, 2008 (Poster 795)
- Efficacy and safety of vicriviroc in HIV-infected treatment-naïve subjects (Study P04875AM3). Available from: http://clinicaltrials.gov/ct2/show/NCT00551018?term=vicriviroc+emtricitabine&rank=1. [Last accessed 10 June 2009]
- Gulick R, Haas D, Collier AC, Two-year follow-up of treatment-experienced patients on vicriviroc (VCV). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA; September 17-20, 2007 (Poster H-1030)
- Dunkle LM, Greaves W, McCarthy MC, Long term safety of vicriviroc. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA; October 25-28, 2008 (Poster H-1269)
- Kasserra C, Soni P, Wan Y, Vicriviroc produces no clinically relevant effects on the QT/QTc interval and central nervous system in healthy individuals. 10th International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, The Netherlands; April 15-17, 2009 (Poster P12)
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1-139. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. [Last accessed 10 June 2009]
- Su Z, Reeves JD, Krambrink A, Response to vicriviroc (VCV) in HIV-infected treatment-experienced subjects using an enhanced Trofile HIV co-receptor tropism assay: reanalysis of ACTG 5211 results. 17th International HIV Drug Resistance Workshop. Sitges, Spain; June 10-14, 2008 (Abstract 88)
- Tsibris AMN, Sagar M, Gulick RM, In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 2008;82:8210-4
- Ogert RA, Hou Y, Ba L, Modification of the CCR5 binding site by mutations in gp120 influence drug susceptibility and viral infectivity in a subject with clinical resistance to vicriviroc. XVIII International HIV Drug Resistance Workshop. Fort Myers, FL, USA; June 9-14, 2009 (Abstract 16)
- Buontempo BJ, Strizki J, Ralston R. HIV isolates resistant to CCR5 antagonists demonstrate increased affinity for the drug-bound coreceptor. 16th International HIV Drug Resistance Workshop. June 12-16, 2007, Barbados. Abstract 122
- Pugach P, Marozsan AJ, Ketas TJ, HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007;361:212-28
- Marozsan AJ, Moore DM, Lobritz MA, Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J Virol 2005;79:7121-34
- Sansone-Parsons A, Keung A, Tetteh E, Renal insufficiency has no clinically significant impact on pharmacokinetics of vicriviroc administered alone or in the presence of a potent CYP3A4 inhibitor. 8th International Workshop on Clinical Pharmacology of HIV Therapy. Budapest, Hungary; April 16-18, 2007 (Poster 5)
- Fätkenheuer G, Hoffmann C, Slim J, Administration of the CCR5 antagonist vicriviroc to patients with HIV/HCV coinfection is safe and well-tolerated. 15th International Symposium on HIV and Emerging Infectious Diseases. Toulon, France; May 28-30, 2008 (Oral presentation)
- Safety immune response to vicriviroc in combination regimens in hiv-infected antiretroviral treatment experienced children and adolescents. Study NCT00766597. Available from: http://clinicaltrials.gov/ct2/show/NCT00766597?term=vicriviroc&rank=11. [Last accessed 4 September 2009]
- Tremblay CL, Giguel F, Kollmann C, Anti-human immunodeficiency virus interactions of SCH-C (sCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob Agents Chemother 2002;46:1336-9
- Zhang C, Xu S, Wei J, Guo H. Predicted co-receptor tropism and sequence characteristics of China HIV-1 V3 loops: implications for the future usage of CCR5 antagonists and AIDS vaccine development. Int J Infect Dis 2009;13:e212-6
- Connell BJ, Michler K, Capovilla A, Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa. AIDS 2008;22:896-9
- Johnston ER, Zijenah LS, Mutetwa S, High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol 2003;77:7682-8
- Roche Laboratories Inc. and Trimeris, Inc. Fuzeon (enfuvirtide) prescribing information. Available from: http://rocheusa.com/products/fuzeon/pi.pdf. [Last accessed 10 June 2009]
- Raltegravir (integrase inhibitor) [11] prescribing information. Available from: http://rocheusa.com/products/fuzeon/pi.pdf. [Last accessed 10 June 2009]
- Tibotec, Inc. Prezista (darunavir) prescribing information. Available from: http://www.prezista.com/prezista/documents/us_package_insert.pdf. [Last accessed 10 June 2009]
- Tibotec, Inc. Intelence (etravirine) prescribing information. Available from: http://www.intelence-info.com/intelence/assets/pdf/INTELENCE_PI.pdf. [Last accessed 10 June 2009]
- Pfizer Inc. Selzentry (maraviroc) prescribing information. Available from: http://media.pfizer.com/files/products/uspi_maraviroc.pdf. [Last accessed 10 June 2009]